Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.
Juniper Pharmaceuticals, after a strategic evaluation, decided to prioritize its resources on the company’s core businesses of Crinone progesterone gel and Juniper Pharma Services. As a result of the changes, Juniper plans to lay off 8 percent of its staff, mostly in the new product research-and-development areas.
One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced that the company was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million.
Novogen updated investors on the company’s strategic review of operations. On June 8, 2017, Iain Ross was appointed as chairman, which triggered the review by the board and management team.
Shares of Gemphire Therapeutics plunged more than 51 percent in morning trading after the company’s Phase IIb anti-cholesterol drug gemcabene failed to meet analyst expectations.
OvaScience named a new chief executive officer and slashed its employee count by half.
A little more than two weeks after being placed on administrative leave, Gur Roshwalb – chief executive officer of Akari Therapeutics – resigned his position.
Danish drugmaker Novo Nordisk said the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to “a potential conflict of interest.”
Immunomedics’ chief executive office and chief scientific officer will step down. Also, Seattle Genetics backed out of a $2 billion deal with the company.
Shares of Regulus Therapeutics were down more than 31 percent in premarket trading as its chief executive officer resigns amid an ongoing clinical hold of its lead product and the company initiates a corporate restructuring plan that includes the termination of 30 percent of employees.